Cargando…
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin (177)Lu-PP-F11N
SIMPLE SUMMARY: Several radiolabeled peptides targeting CCK2R-positive types of cancer (such as medullary thyroid cancer and small cell lung cancer) have been reported in the last 25 years, some of which have entered clinical trials. In an effort to improve its tumor-targeting properties, we applied...
Autores principales: | Grob, Nathalie M., Schibli, Roger, Béhé, Martin, Mindt, Thomas L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199036/ https://www.ncbi.nlm.nih.gov/pubmed/34071914 http://dx.doi.org/10.3390/cancers13112629 |
Ejemplares similares
-
Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2021) -
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2020) -
Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020) -
Signaling Network Response to α-Particle–Targeted Therapy with the (225)Ac-Labeled Minigastrin Analog (225)Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
por: Qin, Yun, et al.
Publicado: (2023) -
SUN-334 Evaluation of the CCK-2 Receptor Agonist (177)Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study
por: Rottenburger, Christof, et al.
Publicado: (2019)